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HPVBackground and purpose: We investigated the effects of socio-demographic, treatment- and tumor-
speciﬁc determinants on the risk of developing a second malignancy among patients treated for cervical
cancer.
Material and methods: We included patients with a ﬁrst cervical cancer (N = 12,048) from the Netherlands
Cancer Registry (NCR), 1989–2008. Standardized incidence ratios (SIR) and absolute excess risks (AER)
per 10,000 person-years were calculated to estimate the burden of second cancers in cervical cancer sur-
vivors. Incidence rate ratios (IRR) were computed to identify predictors for second cancers among cervical
cancer survivors.
Results: During the study period, 676 (5.6%) patients were diagnosed with a second cancer. Smoking-
related cancers contributed the most to the overall burden of second cancers (AER = 21) and risks
remained elevated after 10 years of follow-up (SIR = 1.8, 95% CI: 1.4–2.2), yet it decreased markedly in
the younger birth cohorts. Cervical cancer survivors who underwent radiotherapy were at higher risk
for a second tumor when compared to those without radiotherapy, especially at smoking-related sites
(IRR = 1.6 (1.2–2.3)).
Conclusion: Patients with cervical cancer had a signiﬁcantly increased risk for a second cancer compared
to the general population, especially for smoking- and irradiation-related tumors. Long-term follow-up
suggested the importance of smoking cessation and the beneﬁts of counseling cervical cancer patients
accordingly, particularly those who received radiotherapy.
 2014 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 111 (2014) 374–381Cervical cancer ranks 11th in the most common cancers in
women in the Netherlands, representing 1.6% of all newly diag-
nosed and 1% of all cancer deaths in 2011 [1]. Although incidence
and mortality from cervical cancer have been declining in the
Netherlands over the past decades, the absolute number of newly
diagnosed cases per year has remained more or less stable since
2007; with slight increases since 2001 [1]. The declining mortality
rate can partly be attributed to the successful implementation of
nationwide screening efforts, initiated in 1996, that target women
aged 30–60 years at a screening interval of 5 years [2,3]. This also
implies that the number of women with a history of cervical cancer
has been growing, being about 5000 in 2012 (10-year prevalence)
[1]. Cancer survivors however often live with long-term
consequences of the disease and its treatment, besides being at ahigher risk of developing new primary cancers. This risk has been
quantiﬁed to be 14% higher in cancer survivors in the U.S. when
compared to the general population; for cervical cancer survivors
this was 32% [4]. A report from Australia found a 24% increased risk
after 23 years of follow-up, which was most pronounced in
smoking-related cancers [5].
Persistent infection with the human papillomavirus (HPV) and
smoking are considered the most important risk factors for cervical
cancer. They have been found to not only to act independently
[6–8], but also jointly as smoking was repeatedly found to increase
the risk of invasive cervical cancer among HPV-positive women by
2–3-fold when compared to non-smoking HPV-positive women
[9,10]. Assessing the epidemiology of second cancers can help
understand the underlying causal factors and their interaction
shared by multiple, consecutive cancers as well as the impact of
treatment. Smoking is not only the single most important risk
factor for several cancers, but has been proven to act past the ﬁrst
cancer diagnosis and to affect outcomes of cancer treatment [11]. A
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from Northern Europe and the U.S. highlighted the high risk for
second malignancies in cervical cancer patients receiving high
doses of radiation during treatment, which increased with fol-
low-up and stayed signiﬁcantly elevated even after 40 years [12].
Given the growing number of cervical cancer survivors, coun-
seling cervical cancer survivors regarding the risk of second malig-
nancies and active measures against smoking may need to become
an important indicator for patient and clinicians during follow-up.
In addition, long-term follow-up can teach us about the impact of
smoking and various treatment- and patient-related determinants
on the development of second cancers. Therefore, this study aimed
to study the risk and determinants of secondary cancers in cervical
cancer survivors in the Netherlands and their implication for
cancer prevention.
Material and methods
Data and patient selection
We used population-based data from the nationwide Nether-
lands Cancer Registry (NCR), which combines data from eight
regional Comprehensive Cancer Centers since 1989. Information
on patient characteristics – such as gender, date of birth and
area-based socioeconomic status – as well as tumor characteristics
- such as date of diagnosis, subsite (International Classiﬁcation of
Diseases for Oncology (ICD-O-3) [13]), morphology, stage (Tumor
Lymph Node Metastasis (TNM) classiﬁcation [14–17]) and
treatment – are obtained routinely from the medical records at
about 6–9 months after diagnosis. Completeness is estimated to
be at least 95% [18]. In addition to passive follow-up via hospitals,
date of death is also retrieved from the Municipal Personal Records
Database that contains all deaths or emigrations in the Netherlands
since October 1994. For patients diagnosed before October 1994,
follow-up was completed through NCR by merging the database
with municipality death records or with the Central Bureau for
Genealogy, which registers all deaths in the Netherlands.Deﬁnition of ﬁrst and second cancers
We included all ﬁrst invasive cervical cancers (ICD-O C53;
n = 13,557) in patients age 20+ diagnosed between 1989 and
2008. Second primary cancers were deﬁned using IARC multiple
primary coding rules, i.e. as invasive tumors that occurred in a
different site or tissue than the ﬁrst primary cancer at least
6 months after the ﬁrst cancer diagnosis and is neither an extension,
nor a recurrence, nor a metastasis [13]. Thus, patients with a follow-
up of less than six months after the initial cancer diagnosis were
excluded (n = 132), leaving 12,048 patients for the analysis.Statistical analysis
Standardized incidence ratios (SIR) were calculated in order to
determine the risk of developing a second cancer among cervical
cancer survivors in comparison with the general population. The
number of expected second cancer cases was computed by
applying ﬁve-year age group-, calendar year- and site-speciﬁcTable 1
Categorization* of smoking-, HPV- and radiation-related cancer sites.
Smoking-related
cancers [19]
Oral cavity, oropharynx, nasopharynx, hypopharynx, stom
esophagus, lung/trachea, uterine cervix, ovary, kidney, urin
HPV-related cancers
[20,21]
Anus, vulva, vagina, oropharynx, tonsil, oral cavity
Irradiated sites** [22] Small intestine, colon, rectum, urinary bladder, uterine cor
* Groups are not mutually exclusive (one cancer site can be assigned to several groups;
** Irradiated sites were approximated by cancers of the pelvic region and patients withcancer incidence rates of the general female population to the cor-
responding person-time of cervical cancer patients in the cohort.
SIRs were calculated as the ratio of observed to expected numbers
of patients with second primary cancer and were computed by age
group (<50, 50–69, P70) and follow-up time (6–12 months,
1–5 years, 6–10 years, >10 years). Poisson regression was used to
compute 95% conﬁdence intervals (95% CI).
To measure the overall excess burden of subsequent cancers,
the absolute excess risk (AER) was calculated, representing addi-
tional incidence beyond the background incidence in the general
population. It was deﬁned as the difference between the observed
and the expected number of patients with a second primary can-
cer, divided by the number of person years at risk, multiplied by
10,000. Person years at risk were calculated by summing up
individual follow-up times at the date of ﬁrst cancer diagnosis until
the occurrence of the second cancer, end of study (December 31st,
2008), or death, whichever occurred ﬁrst. All analyses were carried
out for all second cancers combined as well as for the most
common second cancer sites, including lung, breast and colorectal
cancer. Moreover, second malignancies were grouped into
smoking- and HPV-related cancers as well as irradiated sites
according to current scientiﬁc evidence [19–22] (Table 1).
In a second step, the predicted values of socio-demographic-,
tumor- and treatment-related determinants on the risk of develop-
ing a second malignancy were assessed among all cervical cancer
patients in the cohort. We analyzed incidence rate ratios (IRR)
using Poisson regression with the log of the follow-up time as off-
set for all second cancers, breast cancer, smoking-, radiation- and
HPV-related second cancers. Covariates in the model were calendar
year of incidence (continuous), tumor histology (squamous cell
carcinoma, adenocarcinomas or other), stage at ﬁrst cancer
diagnosis (FIGO stage I, II, III, IV or unknown, derived from clinical
TNM), any radiotherapy (yes/no), age at ﬁrst cancer diagnosis
(20–29, 30–49, 50–69 or 70+ years), birth cohort (in quintiles: born
before 1930, 1930–46, 1947–55, 1956–62 or after 1962) and
socioeconomic status (SES) at ﬁrst cancer diagnosis (high, interme-
diate or low). Socioeconomic status scores were obtained from the
Netherlands Institute for Social Research, which were based on
mean income per household, the percentage of households with
a low income and the percentage of households with a low educa-
tion by 4-digit postal code area, each consisting of on average 1765
households. This approach has been used earlier in a study from
the Netherlands, where low SES was found to be associated with
higher cervical cancer incidence and more advanced disease at
diagnosis [23]. The role of birth cohort was only introduced in
the analysis of smoking-related second cancers. Tests for linear
trend were performed by treating the variables age, SES and birth
cohort as continuous.
All statistical analyses were performed in SAS 9.2, SAS Institute,
Cary, NC.Results
Of the 12,048 patients with cervical cancer in the cohort, 676
(5.6%) developed a second primary cancer during the study period,
including 318 (2.6%) smoking-related cancers (among which 147ach, colon, rectum, liver, pancreas, nasal cavity, paranasal sinuses, larynx,
ary bladder, ureter, bone marrow
pus, ovary, vagina, vulva, female genital sites NOS, bone, soft tissue
See Appendix table 1).
those cancers did not necessarily receive actual radiotherapy.
Table 2
Characteristics of cohort diagnosed with invasive cervical cancer in the Netherlands, 1989–2008.
Invasive second cancers after cervical cancer*
First cervical
cancers (n = 12,048)
All second
cancers (n = 676)
HPV-related second








n % n % n % n % n % n %
Age at ﬁrst/second cancer diagnosis (in years)
20–29 614 5.1 1 0.2 1 3.1 1 0.7 0 0.0 0 0
30–49 6356 52.8 167 24.7 10 31.3 32 22.5 60 18.9 61 35.1
50–69 3107 25.8 272 40.2 11 34.4 48 33.8 138 43.4 69 39.7
70+ 1972 16.4 236 34.9 10 31.3 61 43.0 120 37.7 44 25.3
Year of birth
Before 1935 2944 24.4 273 40.4 11 34.4 68 47.9 142 44.7 46 26.4
1935–1951 3012 25.0 222 32.7 13 40.6 43 30.3 111 34.9 62 35.6
1952–1960 2811 23.3 134 19.8 4 12.5 22 15.5 54 17.0 49 28.2
After 1960 3281 27.2 47 7.0 4 12.5 9 6.3 11 3.5 17 9.8
Calendar year of ﬁrst/second cancer diagnosis
1989–1993 2987 24.8 41 6.0 5 15.6 10 7.0 27 8.5 8 4.6
1994–1998 3082 25.6 97 14.4 7 21.9 25 17.6 49 15.4 27 15.5
1999–2003 2891 24.0 211 31.2 10 31.3 37 26.1 103 32.4 53 30.5
2004–2008 3088 25.6 327 48.4 10 31.3 70 49.3 139 43.7 86 49.4
Stage at ﬁrst/second cancer diagnosis
Stage I 6524 54.1 176 26.0 14 43.8 40 28.2 52 16.4 76 43.7
Stage II 2172 18.0 122 18.0 3 9.4 28 19.7 44 13.8 69 39.7
Stage III 2375 19.7 124 18.3 5 15.6 30 21.1 86 27.0 23 13.2
Stage IV 665 5.5 108 16.0 8 25.0 24 16.9 98 30.4 3 1.7
Unknown 312 2.6 146 21.6 2 6.3 20 14.1 38 12.0 3 1.7
Histological type of ﬁrst cancer
Squamous cell carcinoma 9051 75.1 541 80.0 31 96.9 114 80.3 265 83.3 132 75.9
Adenocarcinoma 2011 16.7 96 14.2 0 0.0 23 16.2 38 12.0 27 15.5
Other 986 8.2 39 5.8 1 3.1 5 3.5 15 4.7 15 8.6
Initial treatment of ﬁrst cancer
No radiotherapy 6185 51.3 307 45.4 21 65.6 62 43.7 120 37.7 101 58.0
Any radiotherapy 5863 48.7 369 54.6 11 34.4 80 56.3 198 62.3 73 42.0
Socio-economic status (SES) at diagnosis of ﬁrst cancer
High 3672 30.5 178 26.3 10 31.3 38 26.8 80 25.2 50 28.7
Intermediate 2963 24.6 162 24.0 10 31.3 29 20.4 67 21.1 47 27.0
Low 4756 39.5 268 39.6 9 28.1 53 37.3 138 43.4 60 34.5
Unknown 657 5.5 68 10.1 3 9.4 22 15.5 33 10.4 17 9.8
p-value (chi2), excluding ‘‘unknown’’ <.0001 <.0001 0.9661 0.0253 <.0001 0.4126
Follow-up between ﬁrst and second cancer diagnosis (in years)
Mean 6.4 4.4 5.9 6.2 6.8
Median 6 2 5 5 6
RT no (mean FU) 7.2 4.4 6 7.2 7.7
RT yes (mean FU) 5.6 4.5 6.3 5.6 5.6
FU = follow-up; RT = radiotherapy.
⁄ Occurring 6 months or later after the initial cervical cancer.
a Groupings (smoking-, HPV- and radiation-related sites) may overlap (see Table 1 and See Appendix table 1).
376 Second cancers in cervical cancer survivors(1.3%) lung cancers), 174 (1.4%) breast cancers and 142 (1.2%) can-
cers in irradiated sites (Table 2). The mean age at the ﬁrst cervical
cancer was 49.6 years in the full cohort and 54.9 years among
those who developed a second cancer (results not shown). Mean
age at the second cancer diagnosis was 61.8 years. Whereas more
than half (54.1%) of the ﬁrst cervical cancers were diagnosed in
stage 1 and only 5.5% in stage 4, second cancers were on average
detected in a later stage, especially smoking-related second can-
cers (30.4% in stage 4). Three quarters of the ﬁrst cervical cancers
were squamous cell carcinomas. About 40% of all patients lived
in neighborhoods with a low SES at the time of their ﬁrst cancer
diagnosis.
The median follow-up between the ﬁrst and the second cancer
ranged between 2.0 (HPV-related sites) and 6.0 years (breast can-
cer), and was 5 years for smoking-related cancers and cancers at
irradiated sites. The interval between the ﬁrst and second primary
cancer was signiﬁcantly longer among patients who did not receive
radiotherapy as their initial treatment as compared to those who
did (7.2 vs. 5.6 years).
Patients with a ﬁrst cervical cancer had an 80% increased risk to
develop cancer than the general population (SIR = 1.8; 95% CI:
1.6–1.9) (Table 3). This risk was slightly higher among patientsabove age 70 (SIR = 2.1; 95% CI: 1.8–2.5). The excess number of
all second cancers in the cohort was 34 per 10,000 person-years.
Smoking-related cancers, in particular lung cancer, contributed the
most to the overall burden of second cancers (AER = 21 and 13 per
10,000 person-years, respectively), whereas the highest SIR (12.4,
95% CI: 9.4–16.2) was found for squamous cell carcinomas (SCC)
of the lung. AER was 6 per 10,000 cancer cases at irradiated sites.
The risk of developing a second cancer decreased with increas-
ing interval since the primary diagnosis for many sites, but
remained signiﬁcantly elevated even ten years after the ﬁrst cancer
for all sites (SIR = 1.4; 95% CI: 1.2–1.7), for smoking-related sites
(SIR = 1.8; 95% CI: 1.4–2.2), especially lung cancer (SIR = 2.7; 95%
CI: 1.8–4.0) and for irradiated sites (SIR = 1.4; 95% CI: 1.0–2.0)
(Fig. 1). In contrast, the increased risk for HPV-related cancers in
the ﬁrst ﬁve years after cervical cancer disappeared in later fol-
low-up years.
Among patients with cervical cancer, neither histology nor
stage at the initial cancer diagnosis had an inﬂuence on the
occurrence of a subsequent cancer (Table 4). In contrast, higher
age at the ﬁrst cancer diagnosis (>50 years) increased the risk for
a second cancer, same as having undergone radiotherapy
especially for smoking-related sites (IRR = 1.6; 95% CI: 1.2–2.3).
Table 3
Standardized incidence ratios (SIR) and absolute excess risks (AER) per 10 000 person-years of second primary malignancies by site and age at initial cancer diagnosis in patients
with invasive cervical cancer in the Netherlands, 1989–2008.
Second cancer Age Observed (n) Expected (n) SIR 95% CI AER
All All ages 676 383 1.8 1.6–1.9 34
<50 287 175 1.6 1.5–1.8 18
50–69 245 139 1.8 1.6–2.0 57
P70 148 69 2.1 1.8–2.5 110
Breast All ages 174 138 1.3 1.1–1.5 4
<50 99 81 1.2 1.0–1.5 3
50–69 46 41 1.1 0.8–1.5 3
P70 29 16 1.8 1.2–2.7 18
HPV-related sitesa All ages 32 16 2.0 1.4–2.9 2
<50 15 9 1.7 0.9–2.8 1
50–69 9 4 2.1 0.9–4.0 2
P70 8 2 3.4 1.5–6.9 8
Colorectum All ages 65 46 1.4 1.1–1.8 2
<50 18 12 1.4 0.9–2.3 1
50–69 26 21 1.2 0.8–1.8 3
P70 21 13 1.6 1.0–2.5 11
Smoking-related sitesa All ages 318 135 2.4 2.1–2.6 21
<50 113 50 2.3 1.9–2.7 10
50–69 132 56 2.3 2.0–2.8 40
P70 73 29 2.5 2.0–3.2 61
Lung All ages 147 31 4.7 4.0–5.5 13
<50 50 14 3.5 2.6–4.6 6
50–69 70 13 5.3 4.1–6.7 30
P70 27 4 7.7 5.1–11.2 33
Lung – squamous cell carcinoma All ages 56 5 12.4 9.4–16.2 6
<50 17 2 10.5 6.1–17.0 3
50–69 26 2 11.3 7.3–16.6 13
P70 13 1 22.5 12.0–39 17
Lung – adenocarcinoma All ages 33 10 3.3 2.3–4.7 3
<50 15 5 2.8 1.6–4.7 2
50–69 13 4 3.5 1.8–6.0 5
P70 5 1 5.9 1.9–14.4 6
Irradiated sitesa All ages 142 87 1.6 1.4–1.9 6
<50 53 28 1.9 1.4–2.4 4
50–69 50 38 1.3 1.0–1.7 6
P70 39 21 1.8 1.3–2.5 25
Bold numbers are statistically signiﬁcant at p 6 0.05 level.
a See Table 1 for groupings.
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had an elevated risk for developing a smoking-related second can-
cer (non-signiﬁcant). A marked cohort effect appeared to explain
the higher risk for developing a subsequent smoking-related can-
cer among those born before 1930 (IRR = 1.8; 95% CI: 1.0–3.1)
and between 1930 and 1946 (IRR = 1.9; 95% CI: 1.3–3.0) and the
lower risk among those born after 1946, especially after 1962
(IRR = 0.2; 95% CI: 0.2–0.5) when compared to patients born
between 1947 and 1955.
Discussion
Cervical cancer survivors have an 80% increased risk to develop
a second malignancy when compared to the general population.
This was particularly pronounced for smoking- and irradiation-
related tumors, where risks remained signiﬁcantly elevated even
after ten years of follow-up. Higher age at diagnosis of the cervical
cancer and treatment with radiotherapy were found to be impor-
tant predictors that increased the risk for a second cancer in cervi-
cal cancer survivors. Higher risk of smoking-related cancer was
found in patients who received radiation therapy, underlining the
association between the two risk factors. In addition, a cohort
effect was found for smoking-related sites, with lower risk among
cohort who were born more recently. Our ﬁndings are similar,
however higher, than those from other big population-based stud-
ies from the U.S. (32% increased risk) [24] and Australia (24%) [5].
Possible reasons for this difference might be a shorter follow-up in
our study, as it has been reported earlier that the risk goes downwith longer follow-up duration for most tumors, resulting in less
person-years. Another possibility refers to different population
characteristics such as stage of smoking epidemic. Whereas
Americans and Australians are to-date deep in the ﬁnal stage of
the smoking epidemic with decreasing smoking prevalence since
the 1980s, Dutch women have only recently shown a decreasing
prevalence of smoking starting around the year 2000 [25].
HPV infection is the primary cause of cervical cancer [26], but
also known to be involved in the causation of other sites such as
oral cancers [20]. The mean duration of a prevalent infection with
high oncogenic risk HPV has been estimated to range between 15
and 24 months [27,28]. Clearance of HPV- induced tissue changes
might thus explain the diminishing risk for HPV-related second
cancers after ﬁve years of follow-up. Yet, HPV infection may be
the reason for the variation in risk of HPV-related cancers by
age; risk was especially high in patients older than 70 years. This
might be due to the natural history of HPV infection, normally
affecting mostly the younger age group and clearing off among
older ages. The high incidence of these cancers in older cervical
cancer survivors in our cohort when compared to the general
population increased the risk signiﬁcantly. This suggests that
increasing awareness and counseling on these risks is needed
among cervical cancer survivors. In the future, effective screening
in combination with vaccination of young women against HPV
types 16 and 18 will make cervical cancer a rare disease and the
risk for all other HPV (16–18)-related cancer sites is expected to
decrease. Implemented nationwide in the Netherlands in 2009,
the HPV vaccination program targets girls 12-years of age and
Fig. 1. Standardized incidence ratios (SIR), its 95% conﬁdence intervals and absolute excess risks (AER) per 10,000 person-years of invasive second cancers among cervical
cancer patients by follow-up time after ﬁrst cancer diagnosis, in the Netherlands in 1989–2008 ⁄⁄note: in the group <1 year, only cases with a follow-up P6 months are
included.
378 Second cancers in cervical cancer survivorsprovided free of charge through healthcare professionals. However,
due to many cohorts without vaccination we expect a long lag
period until the effects of the vaccine will be reﬂected in cancer
incidence. As such prevention strategies should remain focused
on other known risk factors, most importantly education on safe
sexual behavior and smoking.
The increased risk for developing a smoking-related subsequent
cancer conﬁrms that smoking is a key risk factor in this patient
group. Smoking-related cancers represented the majority of excess
subsequent cancers after cervical cancer in our study, but also in
other studies [5,24,29]. Smoking has also been found to be signiﬁ-
cantly associated with a poorer survival in cervical cancer patients
[30]. In the Netherlands, the prevalence of smoking in females hasbeen decreasing since the early 1970s [31,32]. Our study also
showed the remarkable decrease of smoking-related cancer rates
among the younger Dutch female cohort. This development would
consequently lead to a declining burden from smoking-related
cancers, including cervical cancer. However, cervical cancer
patients tend to smoke more than the general population and in
view of the early age at diagnosis (<50 years), smoking cessation
at an early age would prospectively be an effective means in the
prevention of this cancer and subsequent cancers. As this not easily
achievable [33], proactive counseling and referral to smoking
cessation clinics are vital for this patient group.
Patients from low socioeconomic backgrounds are at higher risk
to develop cervical cancer [34] and incidence rates are decreasing
Table 4













sites (n = 318)a
,*
Smoking-related
sites (n = 318)a
IRR 95% CI IRR 95% CI IRR 95% CI IRR 95% CI IRR 95% CI IRR 95% CI
Histology
SCC 1.0 1.0 1.0 1.0 1.0 1.0
AC 1.0 (0.8–1.2) 0.9 (0.7–1.3) 0.0 1.3 (0.8–2.0) 0.9 (0.7–1.3) 1.0 (0.7–1.3)
Other 0.9 (0.7–1.1) 1.0 (0.7–1.5) 1380.2 0.6 (0.3–1.2) 0.8 (0.6–1.2) 0.8 (0.6–1.2)
Stage
I 1.0 1.0 1.0 1.0 1.0
II 0.9 (0.7–1.2) 0.7 (0.4–1.2) 0.7 (0.2–3.1) 1.0 (0.6–1.8) 1.1 (0.8–1.5) 0.9 (0.7–1.3)
III 0.8 (0.6–1.0) 0.6 (0.3–1.0) 1.8 (0.5–6.7) 0.8 (0.4–1.5) 0.9 (0.6–1.3) 0.9 (0.6–1.3)
IV 0.7 (0.4–1.2) 0.8 (0.3–2.2) 3.3 (0.6–17.3) 1.1 (0.4–2.8) 0.7 (0.4–1.5) 0.9 (0.5–1.8)
Unknown 1.4 (0.8–2.2) 2.0 (1.0–4.4) 0.0 0 1.9 (0.8–5.1) 1.2 (0.5–2.6) 1.0 (0.5–2.1)
Age at diagnosis
0–29 years 0.3 (0.1–0.7) 0.3 (0.1–1.2) 0.8 (0.1–6.4) 0.6 (0.2–2.5) 0.1 (0.0–0.9) 0.3 (0.0–2.4)
30–49 years 1.0 1.0 1.0 1.0 1.0 1.0
50–69 years 2.0 (1.6–2.4) 1.2 (0.8–1.8) 1.3 (0.5–3.4) 2.5 (1.6–3.9) 2.5 (1.9–3.3) 1.4 (0.9–2.0)
70+ years 2.5 (2.0–3.1) 1.7 (1.0–2.7) 4.7 (1.8–12.6) 4.3 (2.6–7.1) 2.6 (1.9–3.7) 1.5 (0.9–2.6)
p-trend <0.0001 0.0011 0.0260 <0.0001 <0.0001 0.6901
Radiotherapy
No 1.0 1.0 1.0 1.0 1.0 1.0
Yes 1.3 (1.1–1.7) 1.0 (0.7–1.6) 0.4 (0.1–1.1) 1.2 (0.7–1.9) 1.6 (1.2–2.3) 1.9 (1.4–2.7)
SES
High 1.0 1.0 1.0 1.0 1.0
Intermediate 1.1 (0.9–1.3) 1.1 (0.8–1.7) 1.2 (0.5–3.0) 0.9 (0.6–1.5) 1.0 (0.7–1.4) 1.0 (0.7–1.4)
Low 1.1 (1.0–1.4) 1.0 (0.7–1.4) 0.7 (0.3–1.7) 1.1 (0.7–1.6) 1.3 (1.0–1.7) 1.3 (1.0–1.7)
p-trend 0.1528 0.7190 0.3835 0.7661 0.0480 0.0489
Birth cohort
Born before 1930 1.8 (1.0–3.1)
Born between 1930–1946 1.9 (1.3–3.0)
Born between 1947–1955 1.0
Born between 1955–1962 0.7 (0.5–1.2)
Born after 1962 0.2 (0.2–0.5)
p-trend <0.0001
Bold numbers are statistically signiﬁcant at p 6 0.05 level.
a See Appendix table 1 for groupings.
* Additionally adjusted for incidence year (continuous).
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playing an important role here, as the smoking prevalence in the
Netherlands is still high in this population group [32]. At the same
time, infection with a high-risk HPV type is more common in
socially deprived groups, while they are less likely to participate
in cervical cancer screening and vaccination programs [36,37]. Cer-
vical cancer has also been found to be more common in immigrant
women, who are coming from countries with a higher HPV preva-
lence and are more often living in more deprived neighborhoods
[34,38]. Altogether, this makes cervical cancer a main contributor
to socio-economic disparities in cancer in the Netherlands, includ-
ing the risk for second malignancies, which is expected to remain
higher in this group. In our study, patients with low SES had a
slightly higher risk to develop a smoking-related second malig-
nancy than high SES patients, this was however only borderline
statistically signiﬁcant (Table 4). Primary prevention of cervical
cancer (and potential second malignancies) should target low SES
groups in order to curb socioeconomic disparities.
Smoking and radiotherapy are both risk factors for subsequent
cancers and are known to reinforce each other, even if the lungs
only received very little unintended radiation in the case of cervical
cancer treatment. This has already been studied more comprehen-
sively in survivors of Hodgkin’s disease [39]. In our study, women
who underwent radiotherapy exhibited a 30% increased risk for a
second tumor when compared to women without radiotherapy;
for smoking-related sites this ﬁgure was 60%. In line with this,
we found an elevated AER for tumors at irradiated sites that
remained high even after 10 years of follow-up, similar to the ﬁnd-
ings of earlier studies [4,12]. The observed long-term increase inrisk could thus be a reﬂection of the interaction between smoking
and radiotherapy [40]. This highlights the need for smoking cessation,
especially among cervical cancer patients treated with radiotherapy.Limitations
We restricted our analyses to patients who were followed for
more than six months after their initial cervical cancer diagnosis
in order to exclude synchronous cancers. High excess risks shortly
after the initial cancer diagnosis may be ascribed to an exceptional
diagnostic intensity in the course of treatment during the ﬁrst
months of follow-up. From our results, it seems as if we success-
fully controlled for this as shown by a non-signiﬁcant SIR for all
second cancers at 6–12 months after cervical cancer diagnosis.
Yet, we cannot exclude the possibility that cancer survivors may
have increased awareness, increasing demand for detection and
thus higher incidence of cancer when compared to the general
population.
Cervical cancer incidence rate in the Netherlands has dropped
in the past decades due to screening for pre-invasive lesions [41].
Most early, non-invasive cervical cancers are thus no longer
captured by cancer registration and thus not included in our
study. The applied SES measure in this study is ecological and
thus cannot rule out that the effects for SES would be different
if individual SES was used. However, neighborhood data have
been proven to reliably predict socioeconomic differences at the
individual level [42]. No individual-level data on smoking
behavior, HPV infection status and other important lifestyle
factors were available.
Table A1
Overlap between second cancer groupings.*
n Overlap with (n) Overlap (n/%)
Smoking-related HPV-related Irradiated sites
Smoking-related 318 – 10 101 110 (35)
HPV-related 32 10 – 19 29 (91)
Irradiated sites 142 101 19 – 120 (85)
* See Table 1 for deﬁnitions.
380 Second cancers in cervical cancer survivorsConclusion
Cervical cancer survivors in the Netherlands have a 80% higher
risk for a second cancer when compared to the general population.
Smoking-related second cancers contributed most to this excess
burden and high risks persisted for many years, especially in
patients who received radiotherapy as initial treatment. Proactive
counseling to support quitting smoking may prevent subsequent
cancers and could be cost effective especially when targeted to
high-risk populations, e.g. persons with a low SES or patients
treated with radiotherapy. Long-term follow-up emphasized
the importance of primary prevention, namely active smoking
cessation and increasing awareness of adverse effects of concomitant
risk factors, beyond the ﬁrst cancer diagnosis.Conﬂict of interest statement
All authors declare no conﬂict of interest.Appendix A.
See Table A1.
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